New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
18:22 EDTINCYIncyte's Jakafi trials suggest survival benefits for patients with myelofibrosis
Incyte Corporation announced that several analyses from clinical studies of Jakafi were presented at the 2012 American Society of Hematology Annual Meeting. Jakafi, an oral Janus kinase, or JAK, inhibitor, is FDA-approved for the treatment of patients with intermediate or high-risk myelofibrosis, or MF. In long-term results from two randomized Phase III clinical trials -- COMFORT-I and COMFORT-II -- patients with myelofibrosis treated with Jakafi had improved survival over placebo and best available therapy, suggesting an overall survival benefit. Additionally, data from an ongoing Phase II trial suggest that long-term treatment with Jakafi may be a durably efficacious therapy for patients with polycythemia vera.
News For INCY From The Last 14 Days
Check below for free stories on INCY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
07:02 EDTINCYIncyte says FDA approves supplemental labeling for Jakafi
Subscribe for More Information
July 24, 2014
06:57 EDTINCYIncyte trial miss does not impact Jakafi assumptions, says Leerink
Subscribe for More Information
July 23, 2014
16:41 EDTINCYIncyte's Ruxolitinib shows no statistical significance in primary endpoint
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use